Why GTAD EU is the Must Attend Event for Analytical, QC, CMC, and MSAT Teams in 2026
Many meetings touch analytics, but the 7th Gene Therapy Analytical Development Summit puts it at the centre. Across three days, you’ll find a laser-focused programme on characterisation, potency assurance, QC readiness, comparability, and harmonisation, all built specifically for analytical development, QC, CMC, and MSAT leaders. It’s Europe’s only industry-dedicated platform where analytical development is the main pillar, not a side track.
What Makes This Event Different
Deep Technical Content You Can Use
The programme goes beyond boilerplate talks to detail how teams design phase appropriate control strategies; reduce redundancy across ddPCR, ELISA, AUC, HPLC, TEM; and translate lab methods into validated, QC ready assays. Expect candid discussion on lifecycle management, layered control strategies, and robustness under real world constraints.
MHRA, In The Room
With MHRA speakers and a “Regulatory Scenario Workshop” that stress tests a hypothetical QC strategy live, you’ll see how decisions are really made, where innovation is welcomed, where expectations are non negotiable, and how to prepare submissions that read cleanly.
European Developer Context
The audience and faculty reflect the realities of European development: travel tight budgets, increasing late-stage ambitions, and a need to harmonise with US expectations while navigating EU regulators. Benchmark with peers working on the same problems, in the same environment.
Benchmarking That Saves Time (And Money)
From roundtables on NGS disagreements with classical assays to case studies on CTX0001 potency assurance, you’ll learn from real decision points, not hypotheticals. This helps you avoid rework, anticipate regulator questions, and reduce costly assay drift mid-development.
Who Gets the Most Value?
- Analytical Development: Building potency assurance earlier, choosing fit-for-purpose (not over-engineered) panels, planning for validation, and PPQ readiness.
- QC & QA: Making complex cell-based potency assays robust, managing lifecycle and variability, and preparing GMP suitable release methods.
- CMC & MSAT: Connecting high-resolution characterisation outputs to process control, interpreting capsid distribution without defined thresholds, and protecting method intent during tech transfer.
A Programme Built for Real-World Constraints
Workshops anchor the meeting with practical training: designing phase-appropriate, holistic analytical strategies that support IND and clinical entry without wasting time on over-engineering; and building robust QC analytics for ex vivo gene-modified cell therapies under severe material and timeline constraints.
Workshops anchor the meeting with practical, hands-on training. They guide teams through designing phase appropriate and holistic analytical strategies that support IND and clinical entry. The focus is on building methods that are rigorous enough for regulators without wasting time or resources on over-engineering.
You will also explore how to build robust QC analytics for ex vivo gene-modified cell therapies. These sessions highlight how to maintain analytical integrity even when material is limited and timelines are tight.
Uniquely Collaborative Community
This is a meeting with 60+ targeted peers, poster sharing, speed networking, and interactive discussions, making it a space where scientists and managers can ask frank questions, compare datasets, and leave with clearer answers. The format is tuned for depth, not scale.
Explore the Agenda
Preview regulator-led discussions on analytical strategy, alongside hands-on workshops exploring real-world approaches to assay challenges, QC readiness, and potency assurance.
Partner With Us
Position yourself as the go-to solution provider by showcasing your expertise and value to a room full of biopharma KOLs.
Join Biopharma Experts
Engage with analytical development, QC, CMC, and regulatory leaders through structured networking, roundtables, and small-group discussions to accelerate your gene therapy pipelines.